The Uncategorized Fringes: What 9 Misfit Stocks Tell Us About the 2026 MarketGlobal Report·Jul 30 at 04:14 AMLGCY+3.48%ROOT+5.39%
Belite Bio Conference Highlights Tinlarebant Data and New Hope for Retinal DiseasesMarket Beat·Jul 22 at 04:02 PMBLTE-2.41%
Belite Bio (NASDAQ:BLTE) Shares Gap Up - Should You Buy?Market Beat·Jul 22 at 10:00 AMBLTE-2.41%BAC+0.86%
Belite Bio completes FDA filing for tinlarebant in Stargardt disease type 1PUBT·Jul 20 at 07:03 AMBLTE-2.41%
Belite Bio joins H.C. Wainwright ophthalmology virtual conference panel July 22PUBT·Jul 15 at 07:03 AMBLTE-2.41%
Mizuho Securities Sticks to Their Buy Rating for Belite Bio, Inc. ADR (BLTE)Tip Ranks·Jul 13 at 10:55 AMBLTE-2.41%RANK+1.26%
Belite Bio Eyes Priority FDA Review as Tinlarebant Targets Stargardt DiseaseMarket Beat·Jul 9 at 10:02 PMBLTE-2.41%
How Phase 3 DRAGON Trial Data Showcases At Major Conferences At Belite Bio (BLTE) Has Changed Its Investment StorySimplywall·Jul 7 at 10:54 PMBLTE-2.41%
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor SymposiumUnusual Whales·Jul 6 at 07:01 AMBLTE-2.41%
Belite Bio Announces Oral Presentations at Two Upcoming Medical ConferencesUnusual Whales·Jul 6 at 06:02 AMBLTE-2.41%
Belite Bio to present Phase 3 DRAGON tinlarebant topline results at ISCEV symposiumPUBT·Jul 6 at 06:00 AMBLTE-2.41%
Belite Bio CMO Hendrik Peter Scholl reports disposal of ADS worth $1.46 millionPUBT·Jun 22 at 05:06 AMBLTE-2.41%
What Belite Bio (BLTE)'s Completed Tinlarebant NDA Filing Means For ShareholdersSimplywall·Jun 14 at 12:42 AMBLTE-2.41%
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 | BLTE Stock NewsStockTitan·Jun 12 at 12:30 PMBLTE-2.41%
